RIG-I-dependent tumor-intrinsic type I interferon signaling restricts growth in breast cancer 3D culture
Katherine Tin Heng LiuiD, Lise MangianteiD, Roni Levin‐KonigsbergiD, Cristina Sotomayor-VivasiD, Wenting Yang, Kaitlyn K. Spees, Zhicheng MaiD, Jennifer Lee Caswell-JiniD, Christina N. CurtisiD, Michael Cory BassikiD
Abstract
Discovery of key growth drivers that can be targeted for therapy is a central goal in cancer research. While high-throughput CRISPR screens have revolutionized our ability to identify gene dependencies in cancer, most large-scale screens are conducted in two-dimensional (2D) culture systems that fail to recapitulate tumor organization and behavior. To uncover architecture-dependent vulnerabilities in breast cancer, we performed parallel CRISPR interference (CRISPRi) screens in 2D and three-dimensional (3D) cultures of MCF7 cells, an estrogen receptor-positive (ER+) breast cancer model representative of a high risk of relapse, luminal subtype. Knockdown of IFNAR2 and TYK2 conferred a growth advantage in 3D cultures, implicating type I interferon signaling as a tumor-intrinsic suppressor of proliferation in 3D spheroids. Transcriptomic and functional analyses demonstrated that type I IFN signaling is endogenously activated in 3D spheroids via RIG-I-mediated sensing of cytosolic double-stranded RNA, leading to TBK1 activation and induction of interferon-stimulated genes (ISGs). This tumor-intrinsic IFN response slowed proliferation in 3D culture, independent of exogenous stimuli or the presence of immune cells. Analysis of bulk, single-cell, and spatial transcriptomic datasets from breast cancer patients revealed that a subset of tumors exhibit elevated IFN signaling in cancer cells, including in immune-depleted tumor cores, consistent with a tumor-intrinsic IFN signature. Our findings uncover an IFN-mediated growth-suppressive program shaped by 3D tumor architecture, and contribute towards a better understanding of the role of tumor-intrinsic IFN activity.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 1
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Tumor cell intrinsic RIG-I activation co-opts the host microenvironment to drive immune mediated tumor rejection
E. Fraile-Bethencourt, S. Khou, … S. Anand·bioRxiv·Dec 21, 2022
- Type-I interferon signaling is essential for robust metronomic chemo-immunogenic tumor regression in murine triple-negative breast cancer
C. Vergato, K. A. Doshi, … D. J. Waxman·bioRxiv·Dec 5, 2021
- cDC1 and interferons promote spontaneous CD4+ and CD8+ T cell protective responses to breast cancer
R. Mattiuz, C. Brousse, … K. Crozat·bioRxiv·Dec 23, 2020
- USP18 Inhibition Enhances Type I Interferon Signalling and Immune Activation in the Tumour Microenvironment of Triple-Negative Breast Cancer
Chartinun Chutoe, Emily R. Webb, … Alex von Kriegsheim·bioRxiv·Sep 1, 2025
- TGFβ blocks IFNα/β release and tumor rejection in spontaneous mammary tumors
M. V. V. Guerin, F. Regnier, … N. Bercovici·bioRxiv·Jul 9, 2019
- Robust eIF4B levels undermine invasive growth and immune evasion mechanisms in murine triple negative breast cancer models.
R. Smith, L. Z. D. Z. D. Diba, … S. E. Walker·bioRxiv·Sep 16, 2022